PRESS RELEASEAugust 23, 2016

Dr. Steven Narod the First Canadian to Receive the Basser Global Prize for BRCA Research

  • August 23, 2016

August 18, 2016  |  Download Release

TORONTO, August 18, 2016 – Steven Narod, MD, FRCPC, PhD (hon), FRSC, Women’s College Hospital senior scientist, director of the familial breast cancer research unit and a Tier One Canada Research Chair in Breast Cancer, has received the 2016 Basser Global Prize from the Basser Center for BRCA at the University of Pennsylvania’s Abramson Cancer Center.
Dr. Narod is a world leader in the field of breast and ovarian cancer genetics, who has made significant contributions to the knowledge of how to assess cancer risk and reduce its mortality in BRCA1 and BRCA2 mutation carriers. He is the first Canadian scientist to receive the award.

“The Basser Center prides itself on funding the most innovative clinical and translation research projects that are advancing care of individuals living with or at-risk for BRCA1 and BRCA2 mutations,” said Susan Domchek, MD, executive director of the Basser Center for BRCA and the Basser Professor of Medicine in Penn’s Abramson Cancer Center. “Dr. Narod’s seminal work in cancer genetics has made a significant impact on the understanding, future research and treatment of breast and ovarian cancers. We are thrilled to support his ongoing efforts to improve care for these patients.”

As a recipient of the Basser Global Prize, Dr. Narod will receive $100,000 in unrestricted support of his ongoing BRCA1/2 related research efforts, a commemorative sculpture, and a personal $10,000 cash prize, to be awarded at the annual Basser Center for BRCA Scientific Symposium, scheduled May 4-5, 2017. Dr. Narod will give a keynote address at the symposium.

“I am proud to be the first Canadian to receive this award,” said Dr. Narod. “It’s an honour to have my work recognized by one of the world’s leading medical schools and cancer research centers.”

The new funding will support Dr. Narod’s to research efforts to improve care for women at risk of breast and ovarian cancer or living with the disease.

“We will follow our study participants from our database of 6,000 women with BRCA mutations while investigating new strategies in cancer prevention and treatment,” Dr. Narod said.

Women with mutations in BRCA1 and BRCA2 have a high risk of breast or ovarian cancer. The most effective preventive strategy at this time is surgical removal of the breasts and/or ovaries. Over the past 20 years, Dr. Narod’s research has led to numerous discoveries. He was part of the team that discovered the BRCA1 and BRCA2 mutations and he has contributed to the identification of genetic mutations in a number of ethnic populations, including people of French-Canadian, Bahamian and Ashkenazi Jewish descent. His database of over 15,000 women with mutations from 30 countries supports numerous international collaborations. Currently, Dr. Narod’s studies focus on chemoprevention, the early stages of breast cancer, and breast cancer in young women.



About Women’s College Hospital 

For more than 100 years Women’s College Hospital (WCH) has been developing revolutionary advances in healthcare. Today, WCH is a world leader in the health of women and Canada’s leading, academic ambulatory hospital. A champion of health equity, WCH advocates for the health of all women from diverse cultures and backgrounds and ensures their needs are reflected in the care they receive. It focuses on delivering innovative solutions that address Canada’s most pressing issues related to population health, patient experience and system costs. The WCH Institute for Health System Solutions and Virtual Care (WIHV) is developing new, scalable models of care that deliver improved outcomes for patients and sustainable solutions for the health system as a whole. 

For more information about how WCH is transforming patient care and leading health system solutions, visit

Fully affiliated with

A member of